Manufacturing
Are you thinking about innovation in your production department, changing from wet to dry granulation to enhance throughput, reliability and save costs? Then Atacama may well be the right partner for you.
Atacama Labs offers you the full range of production steps for oral solid dosage forms:
For its production, Atacama Labs partnership with Excella GmbH, part of the Fareva Group, one of the top 10 CMOs worldwide, offers you reliable GMP manufacturing services that have been proven over many years of clinical and commercial production. The Excella site is audited by FDA, EMEA, ANVISA, COFEPRIS and registered in more than 20 countries, including Japan. With complete regulatory support, quality assurance and in-house validation we are uniquely equipped to satisfy all your needs.
The cGMP compliant PDG-0260 at Excella's production site is suitable for granulating both development and production batches. In development, the equipment can process small development batches, starting from 200g minimum. In production, the maximum batch size is up to 60 kg / hour equalling 1 ton / day. For higher volume needs we propose a client specific solution with an even larger compactor system delivering up to 4 tons / day.
In the production site, the substances in classes OEB 1 - 3 can be processed .
So if you have a substance with compressibility or flowability problems or if you would very much like to replace wet granulation by dry granulation, Atacama Labs welcomes you to send the substance for evaluation granulation. For further information, please contact us.
Atacama Labs offers you the full range of production steps for oral solid dosage forms:
- Granulation (for encapsulation or direct compression)
- Tabletting
- Aqueous film coating
- Blistering (PVC, PVC/PVDC, ACLAR, Alu/Alu)
- Packaging (blisters and bottles)
- Shipment globally with different packagings
For its production, Atacama Labs partnership with Excella GmbH, part of the Fareva Group, one of the top 10 CMOs worldwide, offers you reliable GMP manufacturing services that have been proven over many years of clinical and commercial production. The Excella site is audited by FDA, EMEA, ANVISA, COFEPRIS and registered in more than 20 countries, including Japan. With complete regulatory support, quality assurance and in-house validation we are uniquely equipped to satisfy all your needs.
The cGMP compliant PDG-0260 at Excella's production site is suitable for granulating both development and production batches. In development, the equipment can process small development batches, starting from 200g minimum. In production, the maximum batch size is up to 60 kg / hour equalling 1 ton / day. For higher volume needs we propose a client specific solution with an even larger compactor system delivering up to 4 tons / day.
In the production site, the substances in classes OEB 1 - 3 can be processed .
Saving on production costs
PDG Technology™ is an innovative production method based on roller compaction / dry granulation. It allows you to produce most any API - where you have to use wet granulation today - with dry granulation. As a valid alternative to today's wet granulation this method allows you to save massively on production costs of up to 30% due to savings in enery consumption and staff as well as higher throughput with a continuing process and increased tabletting speeds.So if you have a substance with compressibility or flowability problems or if you would very much like to replace wet granulation by dry granulation, Atacama Labs welcomes you to send the substance for evaluation granulation. For further information, please contact us.
